Agilent Technologies Inc. (NYSE:A) today announced it is sponsoring a free scientific symposium on exposomics and the etiology of disease. A panel of scientists from Duquesne University, The Children’s Institute of Pittsburgh and The Heinz Endowments will discuss analytical strategies for measuring how environmental exposure impacts human health and chronic disease. The half-day event, “ Regional Perspectives to Integrate Exposure and Exposome Measurement with Effects on Human Health,” will be held Wednesday, Oct. 16, at Duquesne. “The human exposome initiative is a fast-growing field of research that has captured worldwide attention and is driving a new research paradigm,” said Dr. Anthony Macherone, symposium co-host, senior applications chemist for Agilent, and visiting scientist at Johns Hopkins University School of Medicine. “There is growing evidence that 70 to 90 percent of chronic human diseases result from exposure to exogenous and endogenous chemical entities and are not directly attributable to genetic origin.” “Children in western Pennsylvania, for example, appear to be exposed to more toxic chemicals than other children nationwide, and children with autism may process these chemicals differently from other children,” added co-host Dr. H.M. “Skip” Kingston, professor of analytical chemistry at Duquesne and co-director of the University’s Agilent Center of Excellence for Mass Spectrometry. Dr. Kingston and co-researcher Dr. Scott Faber, a developmental pediatrician, have examined environmental pollutants and autism in children and will each conduct separate presentations at the Oct. 16 event. With more than 20 years of experience in the fields of forensics, biotechnology and drug discovery, Dr. Macherone has developed specialized liquid and gas phase chromatography/mass spectrometry techniques and other core laboratory methods for the identification and quantification of chemicals in biological matrices. “The exposome is comprised of an estimated 100,000 chemical entities circulating in the human body that are outside of genetic control and may offer insight into reducing exposure and developing pathways to personalized medicine,” he said.